Axitinib

Evidence Level: L5

Predicted Indications: 4

Axitinib

Pharmacist Assessment Report

Axitinib: Tyrosine kinase inhibitor (VEGFR/PDGFR) → liposarcoma

One-Sentence Summary

Axitinib is an oral kinase inhibitor marketed in Canada under the brand name INLYTA. The TxGNN model predicts it may be effective for liposarcoma, but the support so far is 1 preclinical publication and no registered clinical trials in the data compiled for this report.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	liposarcoma
TxGNN Prediction Score	0.9987
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the data compiled for this report. Axitinib is generally understood to be an antiangiogenic kinase inhibitor acting on VEGFR and PDGFR pathways, which is the basis for the mechanistic link described below.

A 2016 laboratory study reported that axitinib had antiangiogenic and antitumour activity in myxoid liposarcoma cell lines, a rare form of soft-tissue sarcoma. This is consistent with VEGFR/PDGFR inhibition and suggests the prediction is biologically plausible.

However, that study addresses myxoid liposarcoma, one subtype, and is preclinical only. It does not show clinical benefit in patients with liposarcoma as a whole. Because no cited study directly tests axitinib in liposarcoma patients, the evidence level is held at L5 (model prediction with only indirect support).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27822137	2016	Preclinical (in vitro/in vivo)	Sarcoma	Axitinib showed antiangiogenic and antitumour activity against myxoid liposarcoma cell lines, identified in a screen of targeted and chemotherapy agents

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02389649	INLYTA	Not recorded	Not recorded
02389630	INLYTA	Not recorded	Not recorded

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: 100 interacting drugs were identified. Major-level interactions include clarithromycin and dexamethasone. Moderate-level interactions include aprepitant, clotrimazole, miconazole and naltrexone. The remaining entries listed (acid reducers and antacids such as famotidine, ranitidine, rabeprazole, cimetidine, aluminium hydroxide and calcium carbonate) are Minor.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The only supporting evidence is a single preclinical study in one liposarcoma subtype, with no clinical trials. The prediction is a research question rather than a candidate ready for development.

To proceed, the following is needed:

Clinical data (trials or case series) in liposarcoma patients
Mechanism-of-action data to strengthen the mechanistic analysis
Package insert warnings and contraindications from Health Canada for safety screening
A review of the clinically relevant major interactions (clarithromycin, dexamethasone)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.